Clinical Trial Update: Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ITF2357 (histone deacetylase inhibitor) followed by mechlorethamine in relapsed/refractory Hodgkin's lymphoma; study completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• ITF2357 (ITF2357)
• Mechlorethamine (mechlorethamine)

Snippet

Sponsor: Italfarmaco | Conditions: Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-19